Stock BMX BIOMAXIMA S.A.
Add to a list
To use this feature you must be a member
Log inSign up

Financials BioMaxima S.A.

Equities

BMX

PLBIOMX00015

Pharmaceuticals

Delayed Warsaw S.E.
Other stock markets
 07:03:54 2024-06-03 EDT 		5-day change 1st Jan Change
14.9 PLN +10.37% Intraday chart for BioMaxima S.A. +11.19% -9.26%
2023 BioMaxima S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
2023 BioMaxima S.A. Reports Earnings Results for the Half Year Ended June 30, 2023 CI

Valuation

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Capitalization 1 18.61 15.74 13.35 119.2 113.6 106.4
Enterprise Value (EV) 1 22.23 30.45 24.94 126.3 127.9 99.29
P/E ratio 23.1 x -32.7 x -989 x 16.2 x 11.5 x 3.97 x
Yield - - - 0.91% 1.71% 1.95%
Capitalization / Revenue 0.57 x 0.49 x 0.44 x 1.93 x 1.44 x 0.74 x
EV / Revenue 0.68 x 0.95 x 0.81 x 2.05 x 1.62 x 0.69 x
EV / EBITDA 10.3 x 31.1 x 11.4 x 11.3 x 8.81 x 2.71 x
EV / FCF -22.5 x -2.16 x -24.2 x 69 x - 4.63 x
FCF Yield -4.45% -46.3% -4.14% 1.45% - 21.6%
Price to Book 1.08 x 0.94 x 0.81 x 4.6 x 3.89 x 2.03 x
Nbr of stocks (in thousands) 3,730 3,730 3,730 4,320 4,320 4,139
Reference price 2 4.990 4.220 3.580 27.60 26.30 25.70
Announcement Date 18-05-30 19-06-03 20-05-23 21-04-15 22-04-29 23-04-28
1PLN in Million2PLN
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net sales 1 32.9 32.02 30.61 61.75 79.09 143.9
EBITDA 1 2.166 0.98 2.179 11.19 14.51 36.64
EBIT 1 1.084 0.0505 0.7738 9.634 12.94 34.9
Operating Margin 3.3% 0.16% 2.53% 15.6% 16.36% 24.26%
Earnings before Tax (EBT) 1 0.9261 -0.5316 0.1815 8.746 12.78 35.87
Net income 1 0.8057 -0.482 -0.0135 7.365 10.24 28.88
Net margin 2.45% -1.51% -0.04% 11.93% 12.95% 20.08%
EPS 2 0.2160 -0.1292 -0.003619 1.705 2.290 6.480
Free Cash Flow 1 -0.9901 -14.09 -1.031 1.83 - 21.45
FCF margin -3.01% -44.01% -3.37% 2.96% - 14.91%
FCF Conversion (EBITDA) - - - 16.35% - 58.54%
FCF Conversion (Net income) - - - 24.85% - 74.26%
Dividend per Share - - - 0.2500 0.4500 0.5000
Announcement Date 18-05-30 19-06-03 20-05-23 21-04-15 22-04-29 23-04-28
1PLN in Million2PLN
Estimates

Balance Sheet Analysis

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net Debt 1 3.62 14.7 11.6 7.11 14.3 -
Net Cash position 1 - - - - - 7.09
Leverage (Debt/EBITDA) 1.672 x 15.01 x 5.316 x 0.6353 x 0.9831 x -
Free Cash Flow 1 -0.99 -14.1 -1.03 1.83 - 21.4
ROE (net income / shareholders' equity) 4.91% -2.7% 0.08% 34.6% 41.7% 70.8%
ROA (Net income/ Total Assets) 2.6% 0.09% 1.11% 12.4% 14.8% 32%
Assets 1 30.93 -544.6 -1.218 59.16 69.42 90.28
Book Value Per Share 2 4.640 4.490 4.400 6.010 6.760 12.60
Cash Flow per Share 2 0.3500 0.2700 0.1400 1.020 0.6900 3.110
Capex 1 2.17 17.4 1.64 1.88 - 9.88
Capex / Sales 6.59% 54.41% 5.35% 3.05% - 6.87%
Announcement Date 18-05-30 19-06-03 20-05-23 21-04-15 22-04-29 23-04-28
1PLN in Million2PLN
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Diagnostic & Testing Substances Manufacturers

1st Jan change Capi.
BIOMAXIMA S.A. Stock BioMaxima S.A.
-9.26% 14.36M
DAAN GENE CO., LTD. Stock Daan Gene Co., Ltd.
-32.75% 1.26B
GENEREACH BIOTECHNOLOGY CORP. Stock GeneReach Biotechnology Corp.
-19.01% 56.45M
Diagnostic & Testing Substances Manufacturers
  1. Stock Market
  2. Equities
  3. BMX Stock
  4. Financials BioMaxima S.A.